Indogulf Cropsciences Limited — Q2 FY26 earnings call

Call held 13 Nov 2025

Management summary

IGCL reported a resilient Q2 FY26 with 7% YoY revenue growth and significant margin expansion, despite challenges from erratic monsoons and geopolitical issues impacting exports. The company saw strong performance in branded B2C and crop protection, launched 12 new products, and achieved a credit rating upgrade. Management anticipates a stronger H2 driven by favorable weather and continued focus on strategic initiatives.

Highlights

  • Revenue grew 7% YoY in Q2 FY26 to ₹2,483 million, and 20% YoY for H1 FY26 to ₹4,377 million, driven by branded B2C business and strong performance in crop protection.

  • EBITDA increased by 70% YoY to ₹320 million in Q2 FY26 and 26% YoY to ₹419 million in H1 FY26, reflecting enhanced operational efficiency.

  • Profit After Tax (PAT) rose 24% YoY to ₹207 million in Q2 FY26 and 30% YoY to ₹246 million in H1 FY26.

  • Credit rating upgraded to ICRA A- Stable and ICRA A1, and the debt-equity ratio stands at a healthy 0.5x as of September 30, 2025.

  • Successfully launched 12 new products in H1 FY26 across crop protection, plant nutrients, and biologicals, supporting product mix and margin quality.

Concerns

  • Q2 FY26 revenue growth of 7% YoY was below management's prior expectation of 20% due to erratic monsoons and floods, particularly in South India and Odisha.

  • Exports remained challenging in Q2 FY26 due to geopolitical instability in Ethiopia, the Red Sea disruption, and conflicts in Iran and Ukraine.

  • Industry-wide excess rains led to some carry-forward inventory and softer B2C offtake versus expectations.

Key financials

2 periods

Headline

  • Revenue
    2,483 Mn
    YoY +7%
  • EBITDA
    320 Mn
    YoY +70%
  • PAT
    207 Mn
    YoY +24%
  • Return on Capital Employed
    14.1%
  • Debt Equity Ratio
    0.5×

H1

  • Revenue
    4,377 Mn
    YoY +20%
  • EBITDA
    419 Mn
    YoY +26%
  • PAT
    246 Mn
    YoY +30%

What they filed

Q1 FY27: revenue down 12.3%, net profit down 23.1% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue233 98 123 185 246 +6%109 +10%136 +10%162 −12%
EBITDA27 10 20 9 30 +11%11 +12%21 +2%9 +0%
Net profit17 4 10 3 19 +14%4 +11%12 +25%2 −23%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Segment breakdown

  • Crop Protection
    — Contribution
  • Biologicals
    70% Gross Margin
  • Plant Nutrition
    52% Gross Margin
  • Abhiprakash Globus Private Limited
    9% Revenue Contribution Q2
  • New Product Launches (last 3 years)
    3% Revenue Contribution Q2

Capital allocation

  • Capex Capex disclosed
    • Barwasni capacity enhancement and new DF facility
    Of the INR 14 crores raised for capex in the IPO, utilization in Q2 was intentionally minimal as our focus was on seasonal sales. Full-scale deployment begins in Q3, and we expect completion over the next 2 quarters and it will start commissioning from end of this fiscal year.
  • Debt Debt disclosed
    • Repayment Term loan repaid
    Furthermore, during Q2, our credit rating was upgraded to ICRA A- Stable and ICRA A1 removing us from issuer non-cooperating. The return on capital employed for H1FY26 stands at 14.1%. Our debt equity ratio as of September 30, 2025, is 0.5x.

Guidance & targets

Revenue Growth

  • FY26 Revenue Growth Revenue Growth · FY26 · Low confidence 30-35%
    Presently means that 30%-35% may be challenging because of this impact of quarter 2. But I definitely foresee that we will be one of the effective and promising performers as far as industry peers are concerned.

    — Sanjay Aggarwal

Seasonal Performance

  • H2 Performance Seasonal Performance · H2 FY26 · Medium confidence Better than usual
    However, given current reservoir levels and sowing prospects, we expect a better-than-usual H2 this year.

    — Sanjay Aggarwal

Segment Growth

  • Biologicals and Plant Nutrients Growth Segment Growth · Q3 and Q4 FY26 · High confidence Growth
    But we are very hopeful that in Q3 and Q4 biologicals and nutrients will definitely grow and that will be one of the reason of our improvement in EBITDA and PAT.

    — Sanjay Aggarwal

New Product Launches

  • New products for next year New Product Launches · Next year · High confidence 4-5 products
    And for next year, definitely we are planning for some more 4-5 products.

    — Sanjay Aggarwal

  • New products for exports New Product Launches · Q3 or Q4 FY26 · Medium confidence 1-2 products
    Maybe in exports, 1 or 2 products, we are expecting some registrations. Maybe, we will be able to add in Q3 or Q4.

    — Sanjay Aggarwal

New Product Launches (Subsidiary)

  • New products in Abhiprakash New Product Launches (Subsidiary) · Coming years · High confidence 2-3 products
    Yes, of course. In the coming years, we will add 2-3 new products in Abhiprakash also.

    — Sanjay Aggarwal

EBITDA Margin

  • Q1 EBITDA Margin EBITDA Margin · Next year · Medium confidence Improvement
    for the next year, we are planning for improving Q1 performance in terms of EBITDA and PAT also.

    — Sanjay Aggarwal

What to watch in Q3 FY26

Barwasni Capacity & DF Facility Commissioning

End of FY26
Current Full-scale deployment begins in Q3
Target Completion over next 2 quarters, commissioning from end of fiscal year

Why it matters

Successful commissioning will enhance supply reliability and support future growth and margins.

Full-scale deployment begins in Q3, and we expect completion over the next 2 quarters and it will start commissioning from end of this fiscal year.

Risks & concerns

  • Erratic Monsoons and Floods

    high

    Unexpected continuous rains and floods in August and September impacted Q2 sales and led to carry-forward inventory.

    Management acknowledged

  • Geopolitical Instability and Red Sea Disruption

    medium

    Ongoing conflicts in Ethiopia, Iran, Ukraine, and Red Sea disruption made exports challenging in Q2.

    Management acknowledged

  • Commodity Pricing Below MSP

    medium

    Commodity prices for crops like maize and cotton are currently below Minimum Support Price (MSP) in some markets, requiring careful product mix and pricing discipline.

    Management acknowledged

Q&A highlights

8 direct
Q2 FY26 Revenue Growth vs. Expectations Direct
The reason as we all know of the erratic monsoon, even in the month of September, we had a lot of rains, especially in most of the area of South and Odisha, which was very much evident. So, this had an impact on our industry and the flood situation, it was really a force majeure situation.

Addresses the discrepancy between actual Q2 growth (7%) and prior management expectations (20%), attributing it to unforeseen weather events.

Asked by Rishabh Singh

Drivers for H2 FY26 Growth Direct
It will be majorly B2C segment. As I have mentioned that we have one more company, which is a wholly subsidiary of Indogulf, which is Abhiprakash Globus, the Mascot is Giraffe. That will be the most strategic growth driver for Indogulf as a company, as a group, as a whole together and that will improve our brand business.

Clarifies the key segments and strategies expected to drive growth in the second half of the fiscal year, particularly highlighting the B2C segment and subsidiary contribution.

Asked by Deepak Poddar

Biologicals and Plant Nutrients Segment Trajectory and Margins Direct
Of course, the margin profiles are better in biological and nutrients and that is one of our focus area. There had been a little impact in Q2 because the rain was one factor. Another was that the government policy had some changes and there some of these biologicals were not a part of fertilizer control order. So now the framework has been developed and fortunately, our company is one of the few companies whose all products are within that framework.

Provides insight into the strategic importance and margin profile of the biologicals and plant nutrients segments, including the impact of recent regulatory changes.

Asked by Deepak Poddar

Gross Margins for Biologicals and Plant Nutrients Direct
Hi sir, for biologicals we have gross margins of around 70% and for plant nutrients we have the gross margins of approximately 52%.

Offers specific margin data for key growth segments, indicating their potential to enhance overall profitability.

Asked by Deepak Poddar

Impact of Stricter Environmental Norms and European Export Strategy Direct
So to be very frank, our industry is one of the most regulated industry already and most of the compliances and regulatory, you can say they are not by choice, but they are mandatory for our industry to run. ... Presently, the figures are not meaningful as not much export is there to Europe presently of our company. We are majorly exporting to MENA countries and Latin America countries, and our registrations are more towards South Asia Pacific and also Brazil.

Addresses concerns about regulatory compliance costs and clarifies the company's current export focus and strategy for entering the European market with bio-fertilizers and bio-stimulants.

Asked by Ankit Raj

Debt Repayment and Current Debt Levels Direct
We have already paid the debt. And at present, our main debt of term loan has been repaid. Now, only the working capital loans are there. ... Around INR 190 crores.

Confirms the repayment of term loans and provides the current outstanding amount for working capital loans, indicating improved financial health.

Asked by Deepak Poddar

Timing of Demand Recovery Post-Monsoon Direct
The demand will be, you can say, starting from mid of December until February, you can say mid-February or end-February.

Gives a specific timeline for when the company expects to see a recovery in demand following the monsoon disruptions, crucial for H2 outlook.

Asked by Prafull Rai

Quarterly Margin Variation and Future Improvement Direct
So see, ours is a cyclic business. So we have two seasons, Kharif and Rabi. So, as I mentioned to the earlier investor, I think Prafull was there, that January, February in Q4, practically Q2 and Q4 are the best performing months and Q1 and Q3 are broadly the harvesting months. ... for the next year, we are planning for improving Q1 performance in terms of EBITDA and PAT also.

Explains the cyclical nature of margins across quarters due to business mix and outlines plans to improve performance in traditionally weaker quarters like Q1.

Asked by Satyam Agrawal

2 min read 6 chapters

Detailed narrative

Q2 FY26 Performance Overview and Monsoon Impact

Indogulf Cropsciences reported a 7% YoY revenue growth for Q2 FY26, reaching ₹2,483 million, and a 20% YoY growth for H1 FY26, totaling ₹4,377 million. This growth was primarily driven by the branded B2C business, particularly in crop protection. However, the Q2 growth was lower than anticipated due to extended monsoons and floods, especially in South India and Odisha, which created a 'force majeure' situation for the industry.

Operational Efficiency and Profitability Enhancement

The company demonstrated strong operational efficiency, with Q2 FY26 EBITDA increasing by 70% YoY to ₹320 million, and H1 FY26 EBITDA up 26% YoY to ₹419 million. PAT also saw significant growth, rising 24% YoY to ₹207 million in Q2 FY26 and 30% YoY to ₹246 million in H1 FY26. This improvement was attributed to better product mix, tighter in-market execution, and optimized operational leverage.

Strategic Initiatives and Product Innovation

Innovation remains central to IGCL's strategy, with 12 new products launched in H1 FY26 across crop protection, plant nutrients, and biologicals. These launches are already contributing to product mix and margin quality. The multi-brand approach, including the subsidiary Abhiprakash Globus Private Limited (Mascot Giraffe), contributed 9% to Q2 revenue, deepening reach to underserved farmer segments.

Geographical Performance and Export Challenges

Domestic markets showed broad-based growth, with Haryana, Uttar Pradesh, Maharashtra, and Andhra Pradesh reporting significant revenue increases (60%, 25%, 26%, and 22% respectively). However, exports faced challenges in Q2 due to geopolitical instability in Ethiopia, the Red Sea disruption, and conflicts in Iran and Ukraine. The company is actively developing its European market presence for bio-fertilizers and bio-stimulants, with 10 products already quality certified.

Capital Structure and Debt Management

IGCL's financial health improved with a credit rating upgrade to ICRA A- Stable and ICRA A1. The debt-equity ratio stood at 0.5x as of September 30, 2025, and the return on capital employed for H1 FY26 was 14.1%. The company has repaid its main term loan, with only working capital loans of approximately ₹190 crores remaining. Management expects interest costs to reduce by March FY26 due to improved collections.

Outlook for H2 FY26 and Future Growth Segments

Management anticipates a 'better-than-usual' H2 FY26, driven by favorable weather conditions, improved water availability, and enhanced Rabi crop prospects. The biologicals and plant nutrients segments are expected to grow significantly in Q3 and Q4, contributing to improved EBITDA and PAT, supported by a new regulatory framework. The company plans to launch 4-5 new products next year and 2-3 new products for Abhiprakash in coming years.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Chemicals earnings calls